Fortis Healthcare: 5 Key Growth Drivers That Could Take Its Share Price Above ₹1,200

Synopsis: Hospital stock’s strong EBITDA growth faces a sustainability test, driven by execution, expansion, and efficiency gains, while future upside hinges on margins, occupancy, and operating leverage.

This article evaluates whether this Healthcare company can sustain its strong EBITDA growth trajectory, analyzing key drivers such as post-acquisition execution, capacity expansion, improving business mix, and operating efficiencies, while incorporating brokerage views from Motilal Oswal Financial Services on future earnings potential and valuation upside.

With the market capitalization of Rs 72,121 crore, Fortis Healthcare Ltd’ share closed at Rs 955.30 per share, up by 0.17 percent from its previous day’s close. The share of the company has given a return of 354 percent over the last five years.

Brokerage views

Post-Acquisition Transformation: Following the IHH Healthcare acquisition in FY19, Fortis Healthcare has transitioned into a professionally managed hospital chain with improved governance standards and sharper execution. This shift has strengthened operational discipline, enhanced strategic clarity, and restored investor confidence, laying a solid foundation for consistent performance and scalable growth.

Strong Earnings Growth Momentum: Fortis has demonstrated a strong earnings trajectory, delivering an EBITDA CAGR of nearly 33 percent between FY18 and FY26. This growth has been driven by operational efficiencies, cost optimization, and improved occupancy levels, reflecting the company’s ability to extract higher productivity from existing assets while maintaining profitability.

Aggressive Capacity Expansion Strategy: The company is pursuing an aggressive expansion plan, targeting the addition of 400 to 500 beds annually. Funded largely through internal accruals, this expansion enhances long-term revenue visibility and positions Fortis to capture rising healthcare demand, while maintaining a prudent balance sheet and minimizing reliance on external funding.

Improving Business Mix and Margin Outlook: Although diagnostics growth remains relatively moderate, Fortis is witnessing a gradual improvement in its overall business mix. Better integration between hospitals and diagnostics, along with a higher contribution from complex procedures, is expected to support margin expansion and drive sustained profitability over the medium term.

Earnings Growth Outlook: Fortis Healthcare is expected to deliver a steady earnings trajectory, with EBITDA CAGR of around 17 percent and PAT CAGR of nearly 22 percent over FY26–FY28E. This growth is likely to be driven by sustained bed additions, improving Average Revenue Per Occupied Bed (ARPOB), and operating leverage, supporting margin expansion and profitability.

Motilal Oswal Financial Services has initiated coverage on Fortis Healthcare with a Buy rating and a target price of Rs 1,100, implying an upside of around 15.4 percent from the previous close. In a bull-case scenario, the brokerage sees the stock potentially reaching Rs 1,260, indicating nearly 31.8 percent upside.

Conclusion, The positive stance is underpinned by consistent bed additions, strong execution post the IHH acquisition, and improving operational efficiencies. Motilal Oswal expects earnings growth to remain healthy, supported by rising ARPOB, better asset utilization, and operating leverage, reinforcing confidence in Fortis Healthcare’s medium-term growth trajectory.

About the Company

FHL was incorporated in February 1996. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds.

Financial highlights: Revenue from operations rose by 17.4 percent to Rs. 2,265 cr in Q3FY26 from Rs. 1,928 cr in Q3FY25, and the operating margin improved from 19 percent to 22 percent YoY. Accompanied by a Net profit decline of 22.4 percent to Rs. 197 cr in Q3FY26 from Rs. 254 cr in Q3 FY25 over the same period, resulting in an EPS of Rs 2.57 per share in Q3 FY25.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Fortis Healthcare: 5 Key Growth Drivers That Could Take Its Share Price Above ₹1,200 appeared first on Trade Brains.